Author(s) Details:
Alexandru Calin Grigorescu
Compartment of Medical Oncology, Clinical Hospital for Nephrology “Dr Carol Davila”, Calea Grivitei Nr4, Bucharest, Romania
This section is a part of the chapter: Tirosine Kinase Inhibitors (TKI) Used in the Treatment of Non-Small Cell Lung Cancer (NSCLC) Based on Specific Genetic Alterations
“Osimertinib is currently used in first-line treatment of NSCLC (On February 16, 2024, the Food and Drug Administration approved osimertinib with platinum-based chemotherapy for patients with locally advanced or metastatic NSCLC who have EGFR exon 19 deletions or exon 21 L858R mutations” (U.S. Food & Drug Administration, 2025).
“Generally Osimertinib is well tolerated however, the following adverse effects have been described: anxiety, cough, dizziness, fainting, blurred vision, tachycardia, strong or uneven heartbeats, pain in the chest, groin, or legs, especially in the calves, pain, redness, or swelling of the arm or leg. You may also experience: slurred speech, sudden loss of coordination, sudden, severe headache, weakness or numbness in the arm or leg, and difficulty breathing” (Drugs, 2025).
How to Cite
Nasrat, A. M., Nasrat, S. A., Nasrat, R. M., Nasrat, M. M., & Babiker, S. Y. (2025). Helicobacter pylori and Hyperuricemia: Revisiting Gout Diagnosis in Young Adults with Normal Renal Function. Medical Science: Trends and Innovations Vol. 4, 1–8. https://doi.org/10.9734/bpi/msti/v4/3641